News|Articles|October 2, 2002

Pharmaceutical Technology-10-02-2002
Volume 26
Issue 10

FDA Launches Major Review of CGMPs

FDA is set to revise CGMPs to encourage new manufacturing technologies and develop improved agency policies to ensure drug quality and safety.

External Link - article-36195.pdf

Articles in this issue

about 23 years ago

Article

Understanding Pharmaceutical Flows

about 23 years ago

Article

Will CROs Find Opportunity in a Reinvigorated European R&D Sector? Outsourcing Outlook

about 23 years ago

Article

An Overview of the Validation Approach for Moist Heat Sterilization, Part II

about 23 years ago

Article

Cyclodextrins as Sustained-Release Carriers

Newsletter

Get the essential updates shaping the future of pharma manufacturing and compliance—subscribe today to Pharmaceutical Technology and never miss a breakthrough.

Subscribe Now!

Related Content

How 100% Pharmaceutical Tariffs Will Impact Domestic Manufacturing and Supply Chains

ByChristopher Cole

September 26th 2025

Close-up of Medical Ampoule Production Line at Modern Modern Pharmaceutical Factory. Glass Ampoules are being Filled. Medication Manufacturing Process. | Image Credit: © IM Imagery - stock.adobe.com

Stakeholders React to FDA's Push for Quality, Integrity, and Uniformity

ByPatrick Lavery

September 24th 2025

Mercury. Element 80 of the periodic table of chemical elements. | Image Credit: © N. Elkha - stock.adobe.com

Opposing Reactions as RFK Jr. Removes Thimerosal from Flu Vaccines

ByPatrick Lavery

July 24th 2025

Document Review and Quality Control Concept. Document with a checkmark, quality assurance, and process control. auditing, compliance, verification, data inspection, and business workflow management. | Image Credit: © Supatman - stock.adobe.com

A Novel, Enhanced, and Sustainable Approach to Audit Trail Review

ByDiana Russo

July 4th 2025

Silver Spring, MD, USA - June 25, 2022: The FDA White Oak Campus, headquarters of the United States Food and Drug Administration, a federal agency of the Department of Health and Human Services (HHS). | Image Credit: © Tada Images - stock.adobe.com

FDA Posts Slate of Seven Warning Letters Following Company Inspections

ByPatrick Lavery

June 12th 2025

FDA Launches Major Review of CGMPs

Articles in this issue

Newsletter

Related Content

How 100% Pharmaceutical Tariffs Will Impact Domestic Manufacturing and Supply Chains

Stakeholders React to FDA's Push for Quality, Integrity, and Uniformity

Opposing Reactions as RFK Jr. Removes Thimerosal from Flu Vaccines

A Novel, Enhanced, and Sustainable Approach to Audit Trail Review

FDA Posts Slate of Seven Warning Letters Following Company Inspections

Trending on Pharmaceutical Technology

Building Resilience in Pharma: Our Top 10 Questions from CPHI Frankfurt

Everything to Know About Pharmaceutical Tariffs in 2025

Challenges for the Global Manufacturing of Vaccines

Integrating Sustainability into the Core of Pharmaceutical Science

Outsourcing Partners Providing End-to-End Service